$ALMS

Drappa Jorn sold $65K of ALMS

Drappa Jorn (Chief Medical Officer) sold 2,447 shares of ALUMIS INC. (ALMS) at $26.37 on 2026-08-03.

Original reporting
SEC EDGAR · Drappa Jorn
Published Aug 5, 2026, 10:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALMS
Neutral
high confidence
Mentioned
$ALMS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

This provides a fresh datapoint on insider selling activity by the Chief Medical Officer, but it does not include any operational or financial update for the company.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no fundamental trigger in the text.

03

What to watch

Insider sales often have limited predictive power without context such as prior sale patterns, option exercises, or concurrent company disclosures, none of which are provided here.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-08-05, reflecting insider sale disclosed after the 2026-08-03 transaction date.

Background

The article is a SEC Form 4 insider transaction disclosure for ALUMIS Inc. (ALMS).

Company-level read

Ticker impact

$ALMSNeutralHigh confidence
Context

ALUMIS CMO Drappa Jorn filed a Form 4 selling 2,447 shares at $26.37 on 2026-08-03, disclosing new insider activity for ALMS.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

Form 4 insider sales are common and the article provides no accompanying company-specific news (earnings, guidance, contracts, litigation). The disclosed sale size is moderate and lacks a stated 10b5-1 plan, which can add slight interpretive noise but still typically does not drive fundamentals.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan does not necessarily imply negative information; insiders may sell for diversification, taxes, or planned personal liquidity needs.

Key entities

  • ALUMIS INC.

    Company whose insider transaction is disclosed via Form 4.

  • Drappa Jorn

    Chief Medical Officer who sold shares in an open-market transaction.

Related articles

$ALMSMedAI 9/10

Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements

Alumis Inc. (ALMS) shares drew three analyst price-target raises after its Q1 2026 results and progress on envudeucitinib. Chardan lifted its target to $40 from $38 (Buy), Wells Fargo to $51 from $49 (Overweight), and Guggenheim to $34 from $32 (Buy). The company reported $569.5M cash and narrowed net loss to $93.1M; envudeucitinib Week 24 PASI 90/100 results were also cited.